{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:06Z","timestamp":1785514026525,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40265-019-01160-7","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T15:02:30Z","timestamp":1562079750000},"page":"1241-1247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Naldemedine: A Review in Opioid-Induced Constipation"],"prefix":"10.1007","volume":"79","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"issue":"2","key":"1160_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/AJP.0000000000000662","volume":"35","author":"ER Viscusi","year":"2019","unstructured":"Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019;35(2):174\u201388.","journal-title":"Clin J Pain."},{"issue":"1","key":"1160_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","volume":"7","author":"AD Farmer","year":"2019","unstructured":"Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United Eur Gastroenterol J. 2019;7(1):7\u201320.","journal-title":"United Eur Gastroenterol J"},{"key":"1160_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/CEOR.S61602","volume":"6","author":"KS Coyne","year":"2014","unstructured":"Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269\u201381.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"1160_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/papr.12445","volume":"17","author":"RL Rauck","year":"2017","unstructured":"Rauck RL, Hong KJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract. 2017;17(3):329\u201335.","journal-title":"Pain Pract"},{"issue":"2","key":"1160_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000488695","volume":"34","author":"V Andresen","year":"2018","unstructured":"Andresen V, Layer P. Medical therapy of constipation: current standards and beyond. Visc Med. 2018;34(2):123\u20137.","journal-title":"Visc Med"},{"key":"1160_CR6","unstructured":"Shionogi & Co Ltd. Symproic (naldemedine): Japanese prescribing information. 2017. \n                    http:\/\/www.pmda.go.jp\n                    \n                  . Accessed 24 June 2019."},{"key":"1160_CR7","unstructured":"Shionogi & Co Ltd. Symproic\u00ae (naldemedine tablets for oral use): US prescribing information. 2019. \n                    https:\/\/dailymed.nlm.nih.gov\n                    \n                  . Accessed 24 June 2019."},{"key":"1160_CR8","unstructured":"Shionogi. Rizmoic 200 micrograms film-coated tablets: summary of product characteristics. 2019. \n                    https:\/\/www.ema.europa.eu\n                    \n                  . Accessed 24 June 2019."},{"issue":"5","key":"1160_CR9","doi-asserted-by":"publisher","first-page":"e13563","DOI":"10.1111\/nmo.13563","volume":"31","author":"T Kanemasa","year":"2019","unstructured":"Kanemasa T, Koike K, Arai T, et al. Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. Neurogastroenterol Motil. 2019;31(5):e13563.","journal-title":"Neurogastroenterol Motil"},{"issue":"Suppl 4","key":"1160_CR10","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jpain.2016.01.403","volume":"17","author":"E Migoya","year":"2016","unstructured":"Migoya E, Fukumura K, Yamada T, et al. Effect of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist on QT interval [abstract no. 426]. J Pain. 2016;17(Suppl 4):S81.","journal-title":"J Pain"},{"key":"1160_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.690","author":"K Fukumura","year":"2019","unstructured":"Fukumura K, Yamada T, Yokota T, et al. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of naldemedine. Clin Pharmacol Drug Dev. 2019. \n                    https:\/\/doi.org\/10.1002\/cpdd.690\n                    \n                  .","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"1160_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","volume":"2","author":"M Hale","year":"2017","unstructured":"Hale M, Wild J, Reddy J, et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2(8):555\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"34","key":"1160_CR13","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859\u201366.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1160_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","volume":"159","author":"LR Webster","year":"2018","unstructured":"Webster LR, Nalamachu S, Morlion B, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018;159(5):987\u201394.","journal-title":"Pain"},{"key":"1160_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JPR.S175900","volume":"12","author":"Y Saito","year":"2019","unstructured":"Saito Y, Yokota T, Arai M, et al. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies. J Pain Res. 2019;12:127\u201338.","journal-title":"J Pain Res"},{"issue":"17","key":"1160_CR16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Oda K, Tauchi K, et al. Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol. 2017;35(17):1921\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1160_CR17","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/pm\/pnw325","volume":"18","author":"LR Webster","year":"2017","unstructured":"Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017;18(12):2350\u201360.","journal-title":"Pain Med"},{"issue":"Suppl 8","key":"1160_CR18","first-page":"A700","volume":"6","author":"J Tack","year":"2018","unstructured":"Tack J, Hale ME, Yamada T, et al. Safety and efficacy of naldemedine in the treatment of opioid-induced constipation in chronic non-cancer pain in subjects with or without inadequate response to laxatives [abstract no. P1738]. United Eur Gastroenterol J. 2018;6(Suppl 8):A700.","journal-title":"United Eur Gastroenterol J"},{"issue":"Suppl 3A","key":"1160_CR19","first-page":"S80","volume":"23","author":"M Camilleri","year":"2017","unstructured":"Camilleri M, Tack J, Cai B, et al. Naldemedine treatment of opioid-induced constipation improved patient-reported outcomes in subjects with chronic noncancer pain [abstract no. K2]. J Manag Care Spec Pharm. 2017;23(Suppl 3A):S80.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1160_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","volume":"29","author":"N Katakami","year":"2018","unstructured":"Katakami N, Harada T, Murata T, et al. Randomized phase 3 and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018;29(6):1461\u20137.","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"1160_CR21","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","volume":"29","author":"PJ Larkin","year":"2018","unstructured":"Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv111\u201325.","journal-title":"Ann Oncol"},{"issue":"1","key":"1160_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","volume":"156","author":"SD Crockett","year":"2019","unstructured":"Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218\u201326.","journal-title":"Gastroenterology"},{"issue":"8","key":"1160_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S2468-1253(17)30144-9","volume":"2","author":"G Becker","year":"2017","unstructured":"Becker G, Siemens W. Opioid-induced constipation: reflections on efficacy assessment. Lancet Gastroenterol Hepatol. 2017;2(8):540\u20131.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"1160_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2017.76.9349","volume":"36","author":"Y Yagi","year":"2018","unstructured":"Yagi Y, Kosugi K, Tanimoto T. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2018;36(10):1049\u201350.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1160_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/gutjnl-2018-316001","volume":"38","author":"P Luthra","year":"2018","unstructured":"Luthra P, Burr NE, Brenner DM, et al. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut. 2018;38(3):434\u201344.","journal-title":"Gut"},{"issue":"2","key":"1160_CR26","doi-asserted-by":"publisher","first-page":"468.e1","DOI":"10.1016\/j.jpainsymman.2017.08.022","volume":"55","author":"K Sridharan","year":"2018","unstructured":"Sridharan K, Sivaramakrishnan G. Drugs for treating opioid-induced constipation: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. J Pain Symptom Manag. 2018;55(2):468.e1\u2013479.e1.","journal-title":"J Pain Symptom Manag"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01160-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T23:51:24Z","timestamp":1593561084000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01160-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01160-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}